In particular, anti-Ro52/TRIM21 antibody-positive patients were significantly more likely to have overlap with polymyositis/dermatomyositis (6% versus 3%; P = 0.0431) compared with anti-Ro52/TRIM21 antibody-negative patients. Here, TRIM21 is linked to polymyositis.